Company Overview
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors.
Key Financial Figures
- The company reported a basic and diluted net loss per common share (EPS) of $(0.38) for 2025.
- Revenue figures were not reported in the provided financial statements.
- The total net loss for 2025 was $36.1 million.
Additional Financial Insights
- Research and development expenses reached $31.9 million in 2025.
- Year-end cash and cash equivalents totaled $66.0 million.
- This available capital is expected to fund the company’s operations into mid-2027.